Cath Lab Digest - February 2008 - (Page 67)

67 determine appropriate sized devices for use in coronary procedures. The iColor™ Feature enhances image interpretation by adding color to the cross-sectional view, coloring plaque and lumen based on Trace Assist™ for quick image interpretation. The iTint™ Feature overlays color to the IVUS screen at the discretion of the physician. Additional features include the ability to perform a new run with the push of a button and an icon magnification tool. “The enhanced iSize™ Feature is designed to allow improved precision in predicting the appropriate stent length and diameter for the particular lesion being evaluated,” said Lowell Satler, MD of Washington Cardiology Center in Washington D.C. “The added features of the iLab 1.3 System Software, in particular the iSize and iColor Features, preserve the enhanced gray scale image that iLab system is known for while assisting in image interpretation.” For more information, please visit www.bostonscientific.com. ■ ilab® Ultrasound cont. Boston Scientific has introduced enhancements to the iLab System that give physicians the ability to preview device sizing decisions, colorize plaque and blood flow, and overlay color to enrich viewing the IVUS image. Specifically, the iSize™ Feature allows the user to preview device sizing decisions by displaying area and length measurement graphics in the cross-sectional and Longview™ images, and assists the physician to OrbusNeich’s Genous Bio-engineered R Stent has Lower MACE Rate than Paclitaxel-eluting Stents and Sirolimus-eluting Stents in Clinical Trial ™ ™ P atients who received OrbusNeich’s pro-healing stent, the Genous Bio-engineered R stent, had significantly fewer major cardiac adverse events (MACE) than patients who received a paclitaxeleluting stent (PES) (Boston Scientific's Taxus) or a siroliumus-eluting stent (SES (Johnson & Johnson’s Cypher) in a study conducted at Federico II University of Naples in Naples, Italy. The results of the study were presented recently at the XXVIII National Congress of the Italian Society of Invasive Cardiology by Federico Piscione, MD, the study’s principal investigator and a professor with the university’s Division of Cardiology, Department of Clinical Medicine and Cardiovascular Sciences. At clinical follow-up of 10 months, the cumulative MACE rate for the Genous group (GRS) was 4% versus 22% for the combined PES and SES group (drug-eluting stent group, or DES). For the MACE components, the cumulative rate of target vessel revascularization (TVR) was 1% for GRS versus 11.8% for the DES group, the cumulative rate of myocardial infarction (MI) was 1% for GRS versus 7.8% for the DES group, and the cumulative mortality rate was 2% for GRS versus 7.8% for the DES group. In addition, the cumulative rate for stent thrombosis was 2% for GRS versus 5.8% for the DES group. “Our findings suggest that the deployment of Genous stents in a consecutive series of high-risk patients is safe and effective, with a significantly lower in-hospital incidence of MACE and a better long-term clinical outcome when compared to drug-eluting stents,” said Piscione. “Genous is a viable alternative to drug-eluting stents, which have raised many safety concerns among the interventional cardiology community. Unlike PES and SES that elute cytotoxic agents to inhibit neointimal proliferation, Genous attracts circulating endothelial progenitor cells to rapidly build a layer of healthy tissue and promote long-term natural healing.” The study involved 195 consecutive high-risk patients who underwent percutaneous coronary intervention (PCI) with either GRS or DES implantation at the university's cath lab. After PCI, patients who received GRS were prescribed dual antiplatelet therapy for one month, and patients who received DES were prescribed the same therapy for nine months. Complete clinical follow-up was obtained for 100% of the patient population. High risk was defined as advanced age, high rate of conventional risk factors for coronary artery disease, multivessel disease, multivessel stenting, and depressed left ventricular ejection fraction. Genous is coated with an antibody to capture a patient's endothelial progenitor cells, and, therefore, accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of the Genous stent, EPCs can form an endothelial layer over the stent to provide protection against thrombus and minimize restenosis. The stent was developed by OrbusNeich, a global medical device company. For more information about the study, call +390817462234 or send an e-mail to piscione@unina.it. Note: Cath Lab Digest interviewed Dr. Robbert de Winter about the Genous stent in the September 2007 issue. Read the article at: http:// cathlabdigest.com/article/7676 ■ Heart and Stroke Death Rates Steadily Decline; Risks Still Too High N ew mortality data from the Centers for Disease Control and Prevention (CDC) shows that, since 1999, coronary heart disease and stroke age-adjusted death rates are down by 25.8% and 24.4%, respectively. This means that the American Heart Association’s 2010 strategic goal for reducing deaths from coronary heart disease has been achieved, and for stroke nearly achieved — ahead of time. However, potential problems loom for the future, as all of the major risk factors for these leading causes of death are still too high and several are actually on the rise. If this trend continues, death rates could begin to rise again in years ahead. In 1999, the American Heart Association set a strategic goal of reducing the death rates from coronary heart disease and stroke, and reducing the risk factors for these diseases by 25 percent by 2010. The new CDC data notes early success in meeting the coronary heart disease death rate goal, and shows that success is near for the 25 percent reduction in stroke. However, American Heart Association president Dan Jones, MD, said the victory could be short-lived if the risk factors that lead to heart disease and stroke are not also reduced. “This progress in the reduction of death rates is a landmark achievement, and has come about as a result of tremendous efforts from many partners in research, healthcare, government, business and communities,” Jones said. “As encouraging as it is, heart disease and stroke remain the No. 1 and No. 3 causes of death in the United States. We still have remaining goals that we haven’t yet met — reductions in the risk factors that lead to heart disease and stroke, as well as eliminating the striking disparities in care for women and minority populations. We must continue to address those concerns at the same time we continue to support the advances that we know are saving lives today.” The reduction in the death rates for coronary heart disease and stroke equates to approximately 160,000 lives saved in 2005 (the most recent year for which data is available) compared to the 1999 baseline data. If the current mortality trends hold (which will not be the case if the current trends in risk factors are not improved and current quality of care improvements do not continue), the American Heart Association analysts projects that there may be a 36% decline in the age-adjusted coronary heart disease Continued on next page http://www.bostonscientific.com http://cathlabdigest.com/article/7676 http://cathlabdigest.com/article/7676

Table of Contents Feed for the Digital Edition of Cath Lab Digest - February 2008

Cath Lab Digest - February 2008 Bay Regional Medical Center ENDEAVOR IV: A Zotarolimus-Eluting Stent Versus a Paclitaxel-Eluting Stent in a Randomized Clinical Trial A 3D CT Vessel “Roadmap” Over Live Fluoroscopy for Chronic Total Occlusions Contents Clinical Editor’s Corner An Evaluation of Cath Lab Turnaround Time Commentary: An Evaluation of Cath Lab Turnaround Time Excerpts from Chapter 19. STEMI Interventions – Future Perspectives The Potential Clinical Utility of Intravascular Ultrasound Guidance in Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents The Ten-Minute Interview with…Debbie Charlton, RN The Society of Invasive Cardiovascular Professionals (SICP) at Transcatheter Cardiovascular Therapeutics (TCT) 2007 The Cath Lab is a Business: Do You Have the Knowledge to Stay Afloat? Incidence and Predictors of Vascular Complications after Invasive Coronary Procedures: A Prospective Analysis Ask the Clinical Instructor: A Q&A Column for those New to the Cath Lab Volunteer Survey SICP* Section Meetings Calendar What Do You Think? CEU Education Center Clinical & Industry News Classifieds Advertisers Index

Cath Lab Digest - February 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.